UCLA SPORE IN LUNG CANCER

肺癌中的加州大学洛杉矶分校孢子

• 批准号: 7659753
• 负责人: Steven M. Dubinett
• 金额: $ 23.99万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-06-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7659753
• 关键词: Address; Award; Cancer Biology; Cancer Center; Clinical Trials; Collaborations; Comprehensive Cancer Center; Development; Diagnosis; Faculty; Fostering; Gene Mutation; Grant; Informatics; Institutes; Investigation; Laboratories; Leadership; Lung nodule; Malignant neoplasm of lung; Methods; Monitor; Neuropeptides; Pathology; Pliability; Predisposition; Prevention; Program Development; Regulation; Research; Research Personnel; Resources; Risk; Signal Transduction; Specialized Program of Research Excellence; Translational Research; angiogenesis; base; career; chemokine; design; experience; genetic immunotherapy; in vivo; innovation; pre-clinical; programs; tumor

The UCLA Jonsson Comprehensive Cancer Center has designed a Specialized Program of Research Excellence (SPORE) in lung cancer. This multi-disciplinary, translational research program addresses critical questions in a broad based research effort to enhance our understanding of lung cancer biology and develop more effective methods for the prevention diagnosis, and treatment of lung cancer. The UCLA Lung Cancer SPORE is led by experienced lung cancer researchers who have organized investigative teams to develop highly interactive research programs with a strong translational focus. These scientific programs will focus on: 1) Tumor Susceptibility, Genetic Mutations, and Risk of Lung Cancer; 2) A Combined CT-PET Approach to Optimize in vivo Lung Nodule Characterization; 3) Neuropeptide Signaling Antagonists for SCLC Therapy; 4) Genetic Immunotherapy for Lung Cancer; and 5) Chemokine Regulation of Angiogenesis in Lung Cancer. The translational focus of this research will be maintained in each scientific section by teams of both basic and applied investigators. A Developmental Research Program will award 3-5 new grants each years for highly innovative translational research. The selection and progress of these developmental programs will be monitored by the Developmental Programs and Executive Committees, as well as the Internal and External Advisory Boards. A Lung Cancer SPORE Career Development Program designed for both fellows and faculty will be implemented for the career development of translational lung cancer investigators. To promote the strong translational research emphasis we have instituted a Clinical Trials Core that will be responsible for initiating clinical trials that are based on the pre-clinical investigations in each of the laboratories. Additional cores for pathology, informatics and administration will serve to support all of the research programs within the SPORE. In addition to research based at UCLA, our Lung Cancer SPORE Program is designed to foster collaborative interactions regionally and nationally. Accordingly, we have selected an external advisory board comprised of cancer center directions within our region as well as nationally recognized translational lung cancer researchers. In collaboration with the Lung Cancer SPORE leadership, the Internal and External Advisory Boards will continually assess the progress of all aspects of the program. The UCLA Lung Cancer SPORE is designed for maximum flexibility so that resources can be focused on the most promising investigations with the greatest translational potential. The UCLA Lung Cancer SPORE constitutes a highly collaborative, multi-disciplinary translational research program designed to make a significant impact on lung cancer.

加州大学洛杉矶分校琼森综合癌症中心设计了一项肺癌专业卓越研究计划 (SPORE)。这项多学科、转化性研究计划通过广泛的研究工作解决了关键问题，以增强我们对肺癌生物学的理解，并开发更有效的肺癌预防诊断和治疗方法。加州大学洛杉矶分校肺癌 SPORE 由经验丰富的肺癌研究人员领导，他们组织了研究团队来开发具有强烈转化重点的高度互动的研究项目。这些科学计划将重点关注：1）肿瘤易感性、基因突变和肺癌风险； 2) 优化体内肺结节表征的联合 CT-PET 方法； 3）用于SCLC治疗的神经肽信号拮抗剂； 4）肺癌的基因免疫治疗； 5) 肺癌血管生成的趋化因子调节。这项研究的转化重点将由基础研究人员和应用研究人员团队在每个科学部分进行维护。发展研究计划每年将为高度创新的转化研究提供 3-5 项新资助。这些发展计划的选择和进展将由发展计划和执行委员会以及内部和外部顾问委员会进行监督。将为研究员和教员设计的肺癌 SPORE 职业发展计划将实施，以促进转化肺癌研究者的职业发展。为了促进对转化研究的大力重视，我们建立了临床试验核心，负责启动基于每个实验室的临床前研究的临床试验。病理学、信息学和管理的附加核心将用于支持 SPORE 内的所有研究项目。除了加州大学洛杉矶分校的研究之外，我们的肺癌孢子项目还旨在促进区域和全国范围内的协作互动。因此，我们选择了一个外部顾问委员会，由我们地区的癌症中心方向以及国家认可的转化肺癌研究人员组成。内部和外部顾问委员会将与肺癌 SPORE 领导层合作，不断评估该计划各个方面的进展。加州大学洛杉矶分校肺癌 SPORE 旨在实现最大的灵活性，以便资源可以集中在最有前途且具有最大转化潜力的研究上。加州大学洛杉矶分校肺癌 SPORE 是一个高度协作、多学科的转化研究项目，旨在对肺癌产生重大影响。

项目成果

Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer.

• DOI: 10.1186/1479-5876-6-38
• 发表时间: 2008-07-22
• 期刊: Journal of translational medicine
• 影响因子: 7.4
• 作者: Baratelli F;Takedatsu H;Hazra S;Peebles K;Luo J;Kurimoto PS;Zeng G;Batra RK;Sharma S;Dubinett SM;Lee JM
• 通讯作者: Lee JM

Use of low-melting-point primers for bisulfite genomic sequencing: analysis of the H37 lung cancer tumor suppressor gene promoter.

使用低熔点引物进行亚硫酸氢盐基因组测序：H37肺癌抑癌基因启动子的分析。

• DOI: 10.1016/j.ab.2005.05.008
• 发表时间: 2005
• 期刊: Analytical biochemistry.
• 作者: Oh,JulianaJ;Boctor,Baher;Jimenez,CynthiaA;Lopez,RobertoC;Razfar,Ali;Slamon,DennisJ
• 通讯作者: Slamon,DennisJ

Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.

• DOI: 10.1007/s00432-014-1583-9
• 发表时间: 2014-03
• 期刊: Journal of cancer research and clinical oncology
• 影响因子: 3.6
• 作者: Garon EB;Christofk HR;Hosmer W;Britten CD;Bahng A;Crabtree MJ;Hong CS;Kamranpour N;Pitts S;Kabbinavar F;Patel C;von Euw E;Black A;Michelakis ED;Dubinett SM;Slamon DJ
• 通讯作者: Slamon DJ

Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.

• DOI: 10.1097/jto.0b013e31827d525c
• 发表时间: 2013-03
• 期刊: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
• 作者: Garon EB;Pietras RJ;Finn RS;Kamranpour N;Pitts S;Márquez-Garbán DC;Desai AJ;Dering J;Hosmer W;von Euw EM;Dubinett SM;Slamon DJ
• 通讯作者: Slamon DJ

CCL19 reduces tumour burden in a model of advanced lung cancer.

• DOI: 10.1038/sj.bjc.6603061
• 发表时间: 2006-04-10
• 期刊: BRITISH JOURNAL OF CANCER
• 影响因子: 8.8
• 作者: Hillinger, S;Yang, SC;Batra, RK;Strieter, RM;Weder, W;Dubinett, SM;Sharma, S
• 通讯作者: Sharma, S